ReviewNature reviews. Rheumatology2014
Genetic and epigenetic predictors of responsiveness to treatment in RA.
Review in Nature reviews. Rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review.The pharmacogenomics journal · 2020Pooled it
- Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.The pharmacogenomics journal · 2017Pooled it
- Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies.Arthritis research & therapy · 2017Trial
- Preliminary indications of the effect of a brief yoga intervention on markers of inflammation and DNA methylation in chronically stressed women.Translational psychiatry · 2016Trial
- Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.International journal of molecular sciences · 2026Review
- Predictive biomarkers for precision treatment in rheumatoid arthritis: are we there yet?Frontiers in pharmacology · 2026Review
- Threshold Effect of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index on Disease Activity in Rheumatoid Arthritis: Unveiling a Nonlinear Association.Mediators of inflammation · 2026Article
- Engineering CCR2/IFN-γ overexpression in enucleated mesenchymal stem cells enhances therapy for rheumatoid arthritis.Communications biology · 2025Article
- Baseline epigenetics as a biomarker of mepolizumab response in severe asthma.medRxiv : the preprint server for health sciences · 2025Article
- Integrative molecular network analysis of genetic risk factors to infer biomarkers and therapeutic targets for rheumatoid arthritis.PloS one · 2025Article
- Downregulation of BIRC2 hinders the progression of rheumatoid arthritis through regulating TRADD.Immunity, inflammation and disease · 2023Article
- DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis.Biomedicines · 2023Review
- Identification of Cell-Specific Differential DNA Methylation Associated With Methotrexate Treatment Response in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- A fully human connective tissue growth factor blocking monoclonal antibody ameliorates experimental rheumatoid arthritis through inhibiting angiogenesis.BMC biotechnology · 2023Article
- Epigenetic regulation of B cells and its role in autoimmune pathogenesis.Cellular & molecular immunology · 2022Review
- Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?Arthritis research & therapy · 2022Article
- Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?Pharmaceuticals (Basel, Switzerland) · 2022Review
- Journal Club Review of "What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis-Based Approaches to Its Prediction?"ACR open rheumatology · 2022Review
- Ultrasound imaging tracking of mesenchymal stem cells intracellularly labeled with biosynthetic gas vesicles for treatment of rheumatoid arthritis.Theranostics · 2022Article
- Biomimetic Gradient Scaffolds Containing Hyaluronic Acid and Sr/Zn Folates for Osteochondral Tissue Engineering.Polymers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate and TNF-blocking agents are the DMARDs most commonly prescribed for the treatment of rheumatoid arthritis (RA). However, not all patients treated with these nonbiologic and biologic DMARDs respond satisfactorily and few predictors of treatment efficacy have been identified, despite the fact that these therapies have now been available for many years. Many studies have investigated genetic factors that might predict patient responsiveness to therapies used to treat RA, and epigenetic studies regarding response to treatment are expected to accumulate in the literature in the near future. Herein, we review the advances in identifying genetic and epigenetic predictors of therapeutic responses to methotrexate and/or TNF inhibitors in RA that have been made to date, and highlight important considerations for future studies, such as the need for an improved, preferably biological, outcome measure reflecting response to treatment.
Indexed as
Identifiers
24535543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.